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Abstract
Background: Ro52 is an interferon-inducible protein of the tripartite motif family. Antibodies against Ro52 have
been described in patients with different autoimmune diseases, such as systemic lupus erythematosus and
Sjögren’s syndrome, that are often associated with anti-Ro60 antibodies. The Ro52 autoantigen is extraordinarily
immunogenic, and its autoantibodies are directed against both linear and conformational epitopes. The aim of
this study was to evaluate the prevalence of antibodies to the five Ro52 domains, as well as to Ro52 176– to
196–amino acid (aa) and 200–239-aa peptides, in different systemic autoimmune rheumatic diseases (SARDs). We
also aimed to verify whether antibodies to a single domain or domain association could increase their diagnostic
specificity for any SARD.
Methods: Serum samples were obtained from 100 anti-Ro52 antibody–positive patients with SARDs and from
68 controls (50 healthy donors and 18 patients with other autoimmune or allergic diseases). A special line
immunoassay was created containing a full-length Ro52 antigen expressed in insect cells using the baculovirus
system, five recombinant Ro52 antigen fragments [Ro52-1, Ro52-2, Ro52-3, Ro52-4 (partly overlapping Ro52-1 and
Ro52-2), and Ro52-5 (partly overlapping Ro52-2 and Ro52-3)], and two Ro52 peptides (176–196 aa and 200–239 aa),
all expressed in Escherichia coli.
Results: In patients with SARDs, fragment prevalence rates were as follows: Ro52-1 = 3 %, Ro52-2 = 97 %, Ro52-3 = 0 %,
Ro52-4 = 9 %, Ro52-5 = 28 %, Ro52 175–196-aa peptide = 6 %, and Ro52 200–239-aa peptide = 74 %. All control
samples were negative for the full-length Ro52 and for the five fragments tested.
Conclusions: The main epitope of the Ro52 antigen was localized on fragment 2 (aa 125–267), and the majority (97 %)
of SARD sera had antibodies that target this fragment. As most of the samples were positive for fragment 2 and only
some for fragments 4 or 5, which partially overlap fragment 2, it seems that the target epitope is localized in the
middle of fragment 2 or in the area between fragments 4 and 5. No antibody against a single epitope or a
combination of epitopes was linked to any of the single SARDs.
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Background
Historically, the SSA/Ro antigen was described as a
small cytoplasmic ribonucleoprotein complex consisting
of two different proteins, one of 52 kDa (Ro52) and the
other of 60 kDa (Ro60). Subsequently, novel pathogenic
mechanisms and better biochemical characterization led
to consideration of Ro52 no longer as an integral part of
the SSA/Ro ribonucleoprotein [1–4] but as a separate
antigen, even if in about half of cases antibodies to Ro52
co-occur with anti-Ro60 [5].
Although the presence of anti-Ro52 antibodies has
been reported in different systemic autoimmune rheum-
atic diseases (SARDs) [6], the antibody frequency is
higher in idiopathic inflammatory myopathy (IIM) [7, 8],
Sjögren’s syndrome (SjS), and autoimmune liver diseases
[9]. Indeed, the presence of these autoantibodies in
patients with autoimmune hepatitis correlates with a
worse clinical course [10]. However, these autoantibodies
are not completely specific, as they can be detected in
other conditions, such as viral infections (e.g., hepatitis
C virus) and neoplastic diseases [11], and sometimes in
healthy individuals [12, 13].
The diagnostic usefulness of Ro52 monospecificity is
controversial because reports in the literature show a
low diagnostic value for all autoimmune diseases except
IIM [6]. Therefore, anti-Ro52 antibodies have been
classified as myositis-associated autoantibodies, being
detectable mainly in polymyositis patients with anti-
tRNA synthetase syndrome associated with anti-histidyl
tRNA synthetase (anti-Jo1) [14, 15].
In patients with SARDs these antibodies are associated
with inflammatory lung disease [16], and in anti-Ro52–
positive pregnant women antibodies against the 200– to
239–amino acid (aa) sequence of Ro52 can induce fetal
cardiac heart block (CHB) and/or cardiac conduction
defects because of their arrhythmogenic action on the
fetal heart [16–18]. Despite these associations, the real
clinical significance of anti-Ro52 antibodies remains
partially controversial, and for this reason often their
detection does not have a great impact on connective
tissue disease diagnosis [19].
The Ro52 antigen, composed of 475 aa, has been
identified as an interferon (IFN)-inducible protein of the
tripartite motif family of proteins. It has an E3 ligase
function that ubiquitinates IFN regulatory factors and
proteins. It consists of different domains, including two
zinc finger motifs comprising the RING finger, a B-box,
a coiled-coil region (CC), and a C-terminal B30.2
domain (PRY/SPRY) [20] (Fig. 1).
According to the literature, the CC domain is the main
immunogenic region in patients with systemic lupus
erythematosus (SLE), SjS, and IIM. The C-terminal re-
gion of Ro52, containing the B30.2 domain, showed
higher antibody titers only in patients with SjS [21, 22].
Several laboratory methods can be used to detect
antibodies to the full Ro52 molecule (immunoenzymatic
assay, line immunoassay, counterimmunoelectrophoresis,
Western blot, chemiluminescence, and addressable laser
bead immunoassay). Epitope recognition profiles have
been analyzed only in anti-Ro52–positive mothers of chil-
dren with congenital heart block to identify mothers at
high risk for having affected children, and it has been
suggested that a high ratio between antibody titers to
200–239 aa and 176–196 aa could be used as a marker of
heart block risk [16, 17].
This approach stemmed from the observed dominant
response to 200–239 aa in all mothers who gave birth to
affected children, while antibodies against this peptide
were significantly less frequent in mothers who gave
birth to healthy children. Instead, sera from the latter
mothers reacted mainly with epitopes contained within
176–196 aa of the Ro52 protein.
The aim of our present study was to extend the exam-
ination of Ro52 epitope antibody profiles to patients
with SARDs and to assess the prevalence of antibodies
to the five Ro52 fragments and to Ro52 176–196-aa and
Ro52 200–239-aa peptides. Furthermore, as antibodies
against the entire Ro52 molecule are not disease-
specific, we also aimed to evaluate if the antibodies
against any single epitope or a combination of epitopes
could have more disease specificity than antibodies
against the full-length protein.
Material and methods
Patients
Serum samples were obtained from 100 patients with
SARDs and from 68 control subjects (50 healthy blood
donors and 18 patients with other autoimmune or
allergic diseases). The SARD group consisted of 23 pa-
tients with SLE, 34 with SjS, 7 with mixed connective
tissue disease (MCTD), 27 with IIM, 2 with systemic
sclerosis (SSc), and 7 with rheumatoid arthritis. SARD
diagnoses were established according to internationally
validated disease criteria. Patients with SARDs were se-
lected on the basis of presence of anti-Ro52 antibodies
in their sera. Because intermethod variability in meas-
urement of anti-Ro52 antibodies is very high [23–25],
Ro52 antibody presence was preliminarily confirmed using
four different assays: a BioPlex 2200 antinuclear antibody
(ANA) screen (Bio-Rad Laboratories, Hercules, CA, USA)
and ANA Profile 3 EUROLine, Autoimmune Liver Disease
Profile EUROLine, and Myositis Profile 3 EUROLine line
immunoassays (EUROIMMUN, Luebeck, Germany). A
serum sample was considered positive when anti-Ro52
antibodies were confirmed by at least three of these
methods.
Patient consent was not sought, owing to the retro-
spective nature of the study and the fact that it was
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carried out on leftover samples and because all analyses
were performed blindly and patients’ records and infor-
mation remained anonymous.
Serological assays
A special line immunoassay was created that contained
purified full-length Ro52 antigen expressed in insect
cells using the baculovirus system and five recombinant
Ro52 antigen fragments (Ro52-1–Ro52-5, spanning aa
residues 1–127, 125–268, 268–475, 57–180, and 181–320,
respectively), according to UniProt accession number
P19474, produced in Escherichia coli. The immobilized,
metal ion affinity chromatography–purified, His-tagged
fusion proteins were coated as parallel lines onto nitrocel-
lulose membrane.
Sera were incubated in accordance with the manufac-
turer’s standard protocol (EUROIMMUN) (30 minutes in
serum, 30 minutes in anti-human immunoglobulin G/
alkaline phosphatase, and 10 minutes in 5-bromo-4-
chloro-3-indolyl-phosphate/nitro blue tetrazolium sub-
strate). Reaction intensities expressed in grayscale units
were automatically evaluated using commercially available
EUROLineScan software (EUROIMMUN).
Statistical analysis
Tukey’s method was used to check the data for plausibility
and outliers. The statistical evaluation was performed
using the Kruskal-Wallis H test and the maximum
likelihood estimation. The level of statistical significance
was set at α = 0.05. The evaluation was performed using
PASW Statistics 17.0 version 10.0.2 software (SPSS,
Chicago, IL, USA).
Results
Ninety-seven (97 %) of one hundred of the samples
obtained from the patients with SARDs were positive for
antibodies against the Ro52-2 fragment, and all control
samples were negative for the full-length Ro52 and for
all the fragments except one that was positive for the
175–196-aa and 200–239-aa peptides.
In patients with SARDs, the overall fragment prevalence
rates were as follows: Ro52-1 = 3 %, Ro52-2 = 97 %, Ro52-
3 = 0 %, Ro52-4 = 9 %, Ro52-5 = 28 %, Ro52 175–196-aa
peptide = 6 %, and Ro52 200–239-aa peptide = 74 %. The
fragment and peptide prevalence rates in global and single
SARD cohorts are described in Table 1.
Fig. 1 Schematic representation of the Ro52 antigen showing the main immunogenic fragments and structural domains. aa amino acid, ZN Zinc
Table 1 Prevalence of antibodies to full-length Ro52 and Ro52 epitopes and peptides in patients with SARDs and controls
Ro52 epitopes Ro52 peptides
1 2 3 4 5 Full-length Ro52 200–239 aa 175–196 aa
Total SARDs (n = 100) 3 (3 %) 97 (97 %) 0 9 (9 %) 28 (28 %) 100 (100 %) 74 (74 %) 6 (6 %)
MCTD (n = 7) 0 7 (100 %) 0 0 2 (29 %) 7 (100 %) 5 (71 %) 0
Myositis (n = 27) 1 (4 %) 24 (89 %) 0 3 (11 %) 5 (19 %) 27 (100 %) 16 (59 %) 1 (4 %)
RA (n = 7) 0 7 (100 %) 0 0 2 (29 %) 7 (100 %) 5 (71 %) 0
SLE (n = 23) 1 (4 %) 23 (100 %) 0 1 (4 %) 6 (26 %) 23 (100 %) 19 (83 %) 2 (8 %)
SjS (n = 34) 1 (3 %) 34 (100 %) 0 5 (15 %) 13 (38 %) 34 (100 %) 28 (82 %) 3 (9 %)
SSc (n = 2) 0 2 (100 %) 0 0 0 2 (100 %) 1 (50 %) 0
Controls (n = 68) 0 0 0 0 0 0 1 (1 %) 1 (1 %)
MCTD Mixed connective tissue disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, SSc systemic sclerosis, SjS Sjögren’s syndrome, aa amino acid,
SARD systemic autoimmune rheumatic disease
Data are presented as number (%)
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Quantitative antibody values did not differ among the
SARD cohorts for fragments 1, 3, 4, and 5 or for the
175–196-aa peptide, which provided negative results. In
our analysis of the distribution of the intensity of the
positive reactions, we found that antibody levels did not
differ substantially for the full Ro52 molecule, but they
did for fragment 2 (103 ± 38 grayscale units) and for the
200–239-aa peptide (53 ± 49), which displayed a higher
antibody level in the MCTD and SjS cohorts (Fig. 2).
However, no statistically significant combination of
antibodies against fragments and/or peptides implicated
a disease compared with Ro52-2 antibodies marking a
disease on its own (p < 0.001).
Discussion
The most important findings of this study are that the
main epitope of the Ro52 antigen was located in fragment
Ro52-2 and that all patients with SARDs had antibodies
that targeted this epitope. As the majority of the samples
(97 %) were positive for Ro52-2, and only some for Ro52-4
or Ro52-5, it seems that the target epitope is localized in
the middle of fragment Ro52-2 or in the area between
Ro52-4 and Ro52-5. A very small number of samples were
positive for Ro52-1 and for the 175–196-aa peptide; no
samples were positive for fragment Ro52-3.
Anti-Ro52-5 antibodies were the second most frequent
antibodies marking the 28 % of SARDs patients, while
antibodies against the 200–239-aa peptide present on
Ro52-5 and Ro52-2 marked the 74 % of patients with
SARDs, even if in this cohort anti-Ro52-5 antibodies
were sometimes not reacting.
In the area of the 200–239-aa peptide, leucine zipper
structures are present. Leucine zippers are functional
domains involved in protein–protein interactions and in
dimer formations important for DNA binding. The
strong positivity against the 200–239-aa peptide and the
negativity for 175–196-aa peptide observed in all SARD
sera indicate that the anti-Ro52 200–239-aa/176–196-aa
signal intensity ratio is not a marker of a specific SARD
cohort. Thus, the initial observation that the ratio consti-
tutes a relevant marker for predicting fetal CHB and/or
cardiac conduction defects in anti-Ro52–positive pregnant
women [17] cannot be generalized to a SARD population.
Because anti-Ro52 antibodies are not specific for any
given autoimmune rheumatic disease, the main aim of
this experimental study was to find a distinct epitope
Fig. 2 Boxplots (median [interquartile range]) representing distribution
of antibody values (grayscale units) in the different systemic autoimmune
rheumatic disease (SARD) cohorts for full-length Ro52 (a), fragment
Ro52-2 (b), and Ro52 200–239-aa peptide (c). aa amino acid, MCTD
mixed connective tissue disease, RA rheumatoid arthritis, SjS Sjögren’s
syndrome, SLE systemic lupus erythematosus, SSc systemic sclerosis. Rings
and stars indicate outliers and extreme values respectively
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recognition profile for each SARD cohort. However, the
mapping of the specificity of anti-Ro52 antibodies did
not enable identification of a distinct profile in any
SARD cohort, and any antibody combination had added
value compared with anti-Ro52-2 positivity alone. Only
in patients with SjS did we observe a copresence of anti-
Ro52-2 positivity with anti-Ro52-5 (38 %) or anti-Ro52-
4 (15 %) antibodies.
These observations indicate that anti-Ro52-2 was the
main and most important epitope in each single-SARD
cohort. However, we must acknowledge that an im-
portant limitation of this exploratory study resides in the
small number of patients included, especially in some
SARD cohorts, such as SSc and MCTD. Another limita-
tion of the study is that our disease control group did
not include anti-Ro52–positive samples from patients
with autoimmune diseases other than SARDs (e.g.,
patients with autoimmune liver diseases). Indeed, studies
involving a disease control group of anti-Ro52–positive
patients could help to show differences in epitope preva-
lence between SARD and non-SARD groups. Further-
more, because we did not have information on clinical
features for most of the study patients, we were not able
to analyze the serological findings in relation to clinical
data. On the basis of these preliminary data, and given
the potential significance of the present study, future
studies with larger cohorts should be done to confirm
the prevalence rates we found and to evaluate Ro52
epitope association with clinical parameters.
Conclusions
The main epitope of the Ro52 antigen is localized on
fragment 2 (125–267 aa). As most of the samples were
positive for fragment 2 and only some were positive for
fragments 4 or 5, which partially overlap fragment 2, it
seems that the target epitope is localized in the middle
of fragment 2 or in the area between fragments 4 and 5.
The anti-Ro52 200–239-aa/176–196-aa signal intensity
ratio does not represent a helpful tool to mark a SARD
cohort, and no antibody combination was linked to any
of the single SARD diseases. Future research is necessary
to better define the clinical and serological characteris-
tics of anti-Ro52–positive patients with SARD.
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